Access Engagement & HTA Head

📣 إعلان

منذ 7 ساعات تقريباً

	نوع العقد	دوام كامل
	طبيعة الوظيفة	بالموقع
	الموقع	الرياض

وصف الوظيفة

About Johnson & Johnson Innovative Medicine

At Johnson & Johnson, the focus is on healthcare innovation to prevent, treat, and cure complex diseases. The company aims to develop smarter, less invasive treatments and personalized solutions. Through expertise in Innovative Medicine and MedTech, Johnson & Johnson is positioned to innovate across healthcare solutions to impact health globally.

Role Overview: Access Engagement & HTA Head

Johnson & Johnson Innovative Medicine is seeking an Access Engagement & HTA Head to join the Market Access Team in Riyadh, Saudi Arabia. This full-time role reports to the Market Access Director and supports J&J Innovative Medicine Saudi Arabia’s access engagement and Health Technology Assessment (HTA) strategy. The position is responsible for positioning the portfolio for success within the evolving Saudi healthcare system. As a customer- and stakeholder-facing Market Access leader, this role connects policy, HTA, and emerging healthcare models with field access execution. It involves translating external developments into actionable portfolio and account strategies, working closely with HEMAR Leads, SAM, Pricing & Tender, Medical, Commercial, and Regulatory teams. The role requires 5-10 years of experience.

Key Responsibilities

Shape policy and HTA dialogue with the Ministry of Health (MoH), Council of Health Insurance (CNHI)/Council of Health Technology Assessment (CHTA), and Council of Health Insurance (CHI), anticipating evolving evidence, economic, and value requirements.
Lead the Kingdom of Saudi Arabia (KSA) portfolio HTA and Economic Evaluation Study strategy, including Saudi-adapted economic models, local epidemiology, real-world evidence, and appropriate comparators, in partnership with HEMAR and Medical Affairs.
Monitor major healthcare-system developments, including Vision 2030 healthcare transformation, financing reform, and privatization, and translate them into clear access implications, risks, and opportunities for the leadership team.
Activate relevant priorities across HTA and Economic Evaluation Study (EES) activities, strengthening strategic contracting, price protection, value and pricing policy, portfolio value narratives, and stakeholder prioritization.
Represent J&J Innovative Medicine in appropriate policy forums, industry associations, and public-private initiatives.
Establish and deepen strategic relationships with emerging healthcare stakeholders, including CNHI, Health Holding Company (HHC), healthcare clusters, provider economic functions, and purchasing/contracting organizations.
Serve as a key Market Access interface with the transforming healthcare ecosystem, identifying changes early and translating them into actionable access opportunities.
Support the development of innovative access solutions, including value-based agreements, outcomes-based contracting, innovative financing, early-access, and managed-entry approaches, aligned with evolving purchasing and reimbursement models.
Develop high-level health-transformation plans reflecting HHC and cluster priorities and connect these plans with portfolio priorities and launch sequencing.
Apply an integrated planning discipline to strategic access initiatives, with quantified ambition, clear Directly Responsible Individual (DRI) ownership, defined milestones, and regular continue/refine/scale/stop decisions.
Partner with Medical, Commercial, Regulatory, HEMAR, and other Access team members to align portfolio strategies with emerging pathways and strengthen organizational readiness for the new healthcare model.
Build a differentiated customer-facing access engagement model, segmenting stakeholders according to influence, strategic importance, and access impact.
Expand Market Access engagement beyond traditional purchasing stakeholders to include cluster leadership, finance, contracting, HTA committees, insurers, and other emerging access decision-makers.
Establish a disciplined after-action review approach to evaluate stakeholder reach, conversion, follow-through, and value-message effectiveness, translating insights into future engagement priorities.
Connect national access achievements with account-level execution, ensuring formulary and tender wins translate into sustainable patient access and uptake.

Strategic Priorities and Measures of Success

This role is accountable for three strategic priorities, with success measured across impact, execution, and customer engagement:

Shape the environment through HTA, policy, and value dialogue: Measured by HTA/EES portfolio plan delivery, systematic incorporation of external evidence into planning, quality of HTA/value submissions, and progress on policy/HTA-shaping initiatives.
Build for the emerging healthcare model: Measured by strategic engagement plans for priority entities and clusters, conversion of transformation opportunities into executable access initiatives, progression of innovative contracting/access concepts, and integration of account transformation plans with brands and launches.
Move access closer to customers: Measured by coverage of prioritized access stakeholders, quality and effectiveness of strategic customer interactions, conversion of engagement into defined access outcomes, identification and closure of post-formulary/tender implementation gaps, and evidence of access translating into patient uptake.

Experience Required

Candidates should possess 5-10 years of relevant experience in market access, HTA, policy, or a related field within the pharmaceutical or healthcare industry.